Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.

News

09 June 2021

Successful patient event on 9th June

27 representatives of national patient organisations from 10 European countries listened to talks about therapies for cirrhosis and ACLF, research needs and outlook for the future. A lot of interest was shown towards available and new therapies for decompensated cirrhosis and ACLF. The event was organised by ELPA (president Marko Korenjak) and chaired by Prof. Rajiv Jalan, scientific director of EFCLIF.

More news

Events

24 June 2021

ILC 2021: Symposium „Old and new treatments for patients with advanced cirrhosis”

Join the symposium on Thursday, 24th June 2021 from 14-15h CEST which is organised by members of DECISION in the frame of the virtual ILC congress. Topics include:

  • Why and how to modulate the microbiome: example from MICROB-PREDICT study (Shawcross)
  • Old drugs for novel treatment strategies (Posé)
  • Human albumin: from established indications to novel perspectives (Caraceni)
  • System medicine: is it the right track to personalized treatments: example from DECISION study? (Trebicka)
More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more